Hims & Hers to Acquire Eucalyptus for Up to $1.15B, Accelerating Global Digital Health Expansion
HIMS is trading near its 52-week low of $15.575 (2.7% above the low).
Summary
Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an international digital health leader, for up to $1.15 billion, significantly expanding its global footprint and aiming for category leadership in key international markets.
Key Events · M&A and Partnerships · HIMS
-
Major Acquisition Announced
Hims & Hers Health, Inc. has entered into a definitive agreement to acquire Eucalyptus, an international digital health company, for an aggregate consideration of up to approximately $1.15 billion.
-
Strategic International Expansion
The acquisition is expected to accelerate Hims & Hers' global expansion, deepening its presence in the UK, Germany, and Canada, and entering new markets including Australia and Japan.
-
Payment Structure Details
The consideration includes approximately $240 million in upfront cash, $710 million in deferred payments over 18 months, and up to $200 million in earnout payments tied to revenue and adjusted EBITDA targets through early 2029. Hims & Hers has the option to settle the majority of deferred and earnout payments in cash or stock.
-
Eucalyptus Financial Performance
Eucalyptus currently has an annual revenue run-rate (ARR) north of $450 million USD, with triple-digit year-over-year ARR growth in each quarter of calendar year 2025.
Analysis · HIMS · Industrial Applications And Services
Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an Australia-based digital health company, for up to $1.15 billion. This is a highly significant strategic move, representing over 30% of Hims & Hers' current market capitalization, and comes as the company's stock is trading near its 52-week low. The acquisition is designed to accelerate Hims & Hers' vision to become a leading global consumer health platform, expanding its presence in the UK, Germany, and Canada, and entering new markets like Australia and Japan. The payment structure includes $240 million in upfront cash, $710 million in deferred payments, and up to $200 million in earnout payments tied to future financial targets. Hims & Hers retains the option to settle the majority of deferred and earnout payments in cash or stock, providing financial flexibility while also introducing potential future dilution. The integration of Eucalyptus, which boasts an annual revenue run-rate of over $450 million with triple-digit year-over-year growth, is expected to significantly enhance Hims & Hers' international capabilities and market leadership.
At the time of this filing, HIMS was trading at $15.99 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $15.58 to $72.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.